Skip to main content

Research Repository

Advanced Search

Dr Jennifer May's Outputs (13)

Shedding smart light on the effectiveness of chemotherapy: using Raman spectroscopy and machine learning to differentiate the effects of Cytarabine toxicity and crosstalk of leukaemic and bone marrow stromal cells (2021)
Presentation / Conference Contribution

Mesenchymal stromal cells (MSC) protect leukaemic cells from drug-induced toxicity within the bone marrow niche, with increasing evidence of leukaemic impact on supportive stroma. The nucleoside analogue, cytarabine (ara-C), is a front-line agent for... Read More about Shedding smart light on the effectiveness of chemotherapy: using Raman spectroscopy and machine learning to differentiate the effects of Cytarabine toxicity and crosstalk of leukaemic and bone marrow stromal cells.

Use of machine learning-enabled scenario-based teaching in Haematology and Biomedical Science, as a replacement and supplement to traditional tools and in-person teaching during COVID-19 (2021)
Presentation / Conference Contribution

One of the biggest challenges during the COVID-19 pandemic has been maintaining student engagement and providing the best learning experience with limited face-to-face (FTF) contact, and social distancing requirements. Whilst multiple tools are avail... Read More about Use of machine learning-enabled scenario-based teaching in Haematology and Biomedical Science, as a replacement and supplement to traditional tools and in-person teaching during COVID-19.

Leukaemic and bone marrow stromal cells alter cytarabine genotoxicity and cytotoxicity in favour of disease (2019)
Presentation / Conference Contribution

Resistance to therapy remains one of the greatest challenges in the management of the blood and bone marrow (BM) disorder, acute myeloid leukaemia (AML). This study aimed to investigate how leukaemic and BM stromal cells contribute to altered chemo-s... Read More about Leukaemic and bone marrow stromal cells alter cytarabine genotoxicity and cytotoxicity in favour of disease.

Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML). (2019)
Presentation / Conference Contribution

Mesenchymal stromal cells (MSC) are known to protect leukemic cells from drug-induced toxicity within the bone marrow (BM) niche, however, less is known about leukemic impact on supportive MSC. The nucleoside-analogue, cytarabine (Ara-C), is a front-... Read More about Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML)..

Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor (2017)
Presentation / Conference Contribution

This study aimed to develop a 2D leukaemia-stroma model of the bone marrow for analysis of stromal-mediated chemo-protection; known to contribute to chemotherapy resistance. The model must facilitate integration of a bioluminescent biosensor HA1 for... Read More about Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor.

Rapid in vitro testing and characterization of resistance to chemotherapeutic agents daunorubicin and cytarabine in acute myeloid leukaemia (2017)
Presentation / Conference Contribution

Treatment success in leukaemia is impacted by patient resistance to chemotherapy including cytarabine (ara-C) and the anthracycline daunorubicin (DNR) requiring rapid pre-screening testing. DNR is converted to daunorubicinol (DNRol) by carbonyl reduc... Read More about Rapid in vitro testing and characterization of resistance to chemotherapeutic agents daunorubicin and cytarabine in acute myeloid leukaemia.